References
Rosen, M. R., Brink, P. R., Cohen, I. S., Danilo Jr., P., Robinson, R. B., Rosen, A. B., et al. (2008). Regenerative therapies in electrophysiology and pacing. Journal of Interventional Cardiology Electrophysiology, 22(2), 87–98.
Saksena, S. (2005). Prophylactic ICDs: can (and will) the medical marketplace decide their role? Journal of Interventional Cardiology Electrophysiology, 12(3), 175–176.
Epstein, A. E., DiMarco, J. P., Ellenbogen, K. A., Estes 3rd, N. A., Freedman, R. A., Gettes, L. S., et al. (2008). American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices); American Association for Thoracic Surgery; Society of Thoracic Surgeons. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 51(21), e1–62.
Tung, R., Zimetbaum, P., & Josephson, M. E. (2008). A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. Journal of the American College of Cardiology, 52(14), 1111–11121.
Epstein, A. E. (2008). Benefits of the implantable cardioverter-defibrillator. Journal of the American College of Cardiology, 52(14), 1122–1127.
FDA Executive Summary Prepared for the November 20, 2008 meeting of the Circulatory System Devices Panel, P030031/S011 NaviStar ThermoCool RF Ablation Catheters Biosense Webster, Inc. http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAdvisory/details.cfm?mtg=705
Ip, S., Terasawa, T., Balk, E. M., Chung, M., Alsheikh-Ali, A. A., Garlitski, A. C., Lau, J. Comparative Effectiveness of Radiofrequency Catheter Ablation for Atrial Fibrillation. Comparative Effectiveness Review No. 8.: Agency for Healthcare Research and Quality, Rockville, MD. [in press]. www.effectivehealthcare.ahrq.gov/reports/final.cfm
Jaïs, P., Cauchemez, B., Macle, L., Daoud, E., Khairy, P., Subbiah, R., et al. (2008). Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation, 118(24), 2498–505.
Hohnloser, S. H., Connolly, S. J., Crijns, H. J., Page, R. L., Seiz, W., & Torp-Petersen, C. (2008). Rationale and design of ATHENA: A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients with Atrial fibrillation/atrial flutter. Journal of Cardiovascular Electrophysiology, 19(1), 69–73 Reported at the Late Breaking Clinical Trials Sessions at Heart Rhythm Society Annual Scientific Sessions, Denver, Colorado, May 2008..
Pedersen, O. D., Bagger, H., Keller, N., et al. (2001). for the Danish Investigations of Arrhythmia and Mortality ON Dofetilide Study Group: Efficacy of Dofetilide in the Treatment of Atrial Fibrillation-Flutter in Patients With Reduced Left Ventricular Function A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) Substudy. Circulation, 104, 292–296.
Deedwania, P. C., Singh, B. N., Ellenbogen, K., et al. (1998). Patients With Heart Failure and Atrial Fibrillation : Observations from the Veterans Affairs Congestive Heart Failure Survival Trial of Antiarrhythmic Therapy (CHF-STAT). Circulation, 98, 2574–2579.
Singh, B. N., Singh, S. N., Reda, D., et al. (2005). for the SAFE-T investigators: Amiodarone versus Sotalol for Atrial Fibrillation. New England Journal of Medicine, 352, 1861–72.
Hsu, L. F., Jaïs, P., Sanders, P., Garrigue, S., Hocini, M., Sacher, F., et al. (2004). Catheter ablation for atrial fibrillation in congestive heart failure. New England Journal of Medicine, 351(23), 2373–83.
Prakash, A., Saksena, S., Ziegler, P. D., Lokhandwala, T., Hettrick, D. A., Delfaut, P., et al. (2005). Dual site right atrial pacing can improve the impact of standard dual chamber pacing on atrial and ventricular mechanical function in patients with symptomatic atrial fibrillation: further observations from the dual site atrial pacing for prevention of atrial fibrillation trial. Journal of Cardiovascular Electrophysiology, 12(3), 177–87.
Madan, N., & Saksena, S. (2004). Long-term rhythm control of drug-refractory atrial fibrillation with “hybrid therapy” incorporating dual-site right atrial pacing, antiarrhythmic drugs, and right atrial ablation. American Journal of Cardiology, 93(5), 569–75.
Pappone, C., Radinovic, A., Manguso, F., Vicedomini, G., Ciconte, G., Sacchi, S., et al. (2008). Atrial fibrillation progression and management: a 5-year prospective follow-up study. Heart Rhythm, 5(11), 1501–7.
Rights and permissions
About this article
Cite this article
Evidence Based Medicine and Atrial Fibrillation Ablation: 2009 and The View Beyond. J Interv Card Electrophysiol 24, 1–3 (2009). https://doi.org/10.1007/s10840-009-9363-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10840-009-9363-1